Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer's
The Alzheimer’s field is keeping its perfect record for failure in pivotal Phase III studies.
Merck today scrapped the last remaining Phase III study of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
